Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.

IF 20.9 1区生物学 Q1 INFECTIOUS DISEASES Lancet Microbe Pub Date : 2024-10-22 DOI:10.1016/j.lanmic.2024.100992

Daniela Melchiorri, Tamarie Rocke, Richard A Alm, Alexandra M Cameron, Valeria Gigante

{"title":"Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.","authors":"Daniela Melchiorri, Tamarie Rocke, Richard A Alm, Alexandra M Cameron, Valeria Gigante","doi":"10.1016/j.lanmic.2024.100992","DOIUrl":null,"url":null,"abstract":"<p><p>Antimicrobial resistance continues to evolve and remains a leading cause of death worldwide, with children younger than 5 years being among those at the highest risk. Addressing antimicrobial resistance requires a comprehensive response, including infection prevention efforts, surveillance, stewardship, therapy appropriateness and access, and research and development. However, antimicrobial research and development is limited and lags behind the output of other fields, such as that of cancer or HIV research. The 2023 WHO analysis of the global antibacterial clinical pipeline serves as a tool to monitor and guide research and development efforts. The analysis emphasises the remaining gaps in developing a robust and effective antibacterial drug pipeline, drawing insights from trend analyses and assessment of the innovation potential of candidate antimicrobials. In the present analysis, we evaluated the activity of antibiotics against the new WHO bacterial priority pathogens list 2024, which reflects changing trends in resistance patterns, distribution of bacterial infections, and the emergence of new resistance mechanisms.</p>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Microbe","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.lanmic.2024.100992","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Antimicrobial resistance continues to evolve and remains a leading cause of death worldwide, with children younger than 5 years being among those at the highest risk. Addressing antimicrobial resistance requires a comprehensive response, including infection prevention efforts, surveillance, stewardship, therapy appropriateness and access, and research and development. However, antimicrobial research and development is limited and lags behind the output of other fields, such as that of cancer or HIV research. The 2023 WHO analysis of the global antibacterial clinical pipeline serves as a tool to monitor and guide research and development efforts. The analysis emphasises the remaining gaps in developing a robust and effective antibacterial drug pipeline, drawing insights from trend analyses and assessment of the innovation potential of candidate antimicrobials. In the present analysis, we evaluated the activity of antibiotics against the new WHO bacterial priority pathogens list 2024, which reflects changing trends in resistance patterns, distribution of bacterial infections, and the emergence of new resistance mechanisms.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

解决抗生素开发中的当务之急：世界卫生组织 2023 年抗菌药物临床管线分析的启示。

抗菌药耐药性不断演变，仍然是全球死亡的主要原因之一，5 岁以下儿童的风险最高。解决抗菌药耐药性问题需要采取全面的应对措施，包括感染预防工作、监测、监管、治疗的适宜性和可及性以及研发。然而，抗菌药物的研发工作十分有限，落后于癌症或艾滋病毒研究等其他领域的成果。世卫组织对2023年全球抗菌药物临床管线的分析是监测和指导研发工作的工具。该分析从候选抗菌药物的趋势分析和创新潜力评估中汲取灵感，强调了在开发稳健有效的抗菌药物管线方面仍存在的差距。在本分析中，我们评估了抗生素对 2024 年世卫组织细菌优先病原体新清单的活性，该清单反映了耐药性模式、细菌感染分布和新耐药机制出现的变化趋势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Lancet Microbe Multiple-

CiteScore

27.20

自引率

0.80%

发文量

278

审稿时长

6 weeks

期刊介绍： The Lancet Microbe is a gold open access journal committed to publishing content relevant to clinical microbiologists worldwide, with a focus on studies that advance clinical understanding, challenge the status quo, and advocate change in health policy.